The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components? - 05/12/15

Doi : 10.1016/j.diabet.2015.04.006

J. Harding ^a,^b,^⁎,^{^{1
Joint authorship.}} , M. Sooriyakumaran ^a,^b,^{^{1
Joint authorship.}}, K.J. Anstey ^c, R. Adams ^d, B. Balkau ^e, T. Briffa ^f, T.M.E. Davis ^g, W.A. Davis ^g, A. Dobson ^h, G.G. Giles ^b,^i,^j, J. Grant ^k, M. Knuiman ^f, M. Luszcz ^l, P. Mitchell ^m, J.A. Pasco ^n,^o, C. Reid ^p, D. Simmons ^q,^r, L. Simons ^s, A. Tonkin ^p, M. Woodward ^t,^u, J.E. Shaw ^a,^b,^{^{1
Joint authorship.}}, D.J. Magliano ^a,^b,^{^{1
Joint authorship.}}
^a Department of Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
^b Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
^c Research School of Population Health, the Australian National University, Canberra, Australia
^d The Health Observatory Discipline of Medicine, the University of Adelaide, Adelaide, Australia
^e Inserm, U1018, Centre for Research in Epidemiology and Population Health, France
^f School of Population Health, the University of Western Australia, Crawley, Australia
^g School of Medicine and Pharmacology, the University of Western Australia, Fremantle, Australia
^h School of Population Health, the University of Queensland, Brisbane, Australia
ⁱ Cancer Epidemiology Centre, the Cancer Council Victoria, Melbourne, Australia
^j Centre for Epidemiology and Biostatistics, School of Population and Global Heath, the University of Melbourne, Melbourne, Australia
^k Population Research & Outcome Studies, the University of Adelaide, Adelaide, Australia
^l Flinders Centre for Ageing Studies, Flinders University, Adelaide, Australia
^m Westmead Millennium Institute, the University of Sydney, Sydney, Australia
ⁿ IMPACT Strategic Research Centre School of Medicine, Deakin University, Geelong, Australia
^o NorthWest Academic Centre, Department of Medicine, the University of Melbourne, St Albans, Australia
^p School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
^q School of Medicine, University of Western Sydney, Campbelltown, Australia
^r Department of Rural Health, the University of Melbourne, Shepparton, Australia
^s UNSW Australia Lipid Research Dept, St Vincent's Hospital, Sydney, Australia
^t The George Institute for Global Health, the University of Sydney, Sydney, Australia
^u The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, UK

^*Corresponding author. Level 4, 99 Commercial Road, Melbourne, VIC, Australia, 3004. Tel.: +61 3853 21582; fax: +61 3853 21100.

conectar o crear una cuenta

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Aims

The metabolic syndrome (MetS) is a risk factor for cancer. However, it is not known if the MetS confers a greater cancer risk than the sum of its individual components, which components drive the association, or if the MetS predicts future cancer risk.

Materials and methods

We linked 20,648 participants from the Australian and New Zealand Diabetes and Cancer Collaboration with complete data on the MetS to national cancer registries and used Cox proportional hazards models to estimate associations of the MetS, the number of positive MetS components, and each of the five MetS components separately with the risk for overall, colorectal, prostate and breast cancer. Hazard ratios (HR) and 95% confidence intervals (95%CI) are reported. We assessed predictive ability of the MetS using Harrell's c-statistic.

Results

The MetS was inversely associated with prostate cancer (HR 0.85; 95% CI 0.72-0.99). We found no evidence of an association between the MetS overall, colorectal and breast cancers. For those with five positive MetS components the HR was 1.12 (1.02-1.48) and 2.07 (1.26-3.39) for overall, and colorectal cancer, respectively, compared with those with zero positive MetS components. Greater waist circumference (WC) (1.38; 1.13-1.70) and elevated blood pressure (1.29; 1.01-1.64) were associated with colorectal cancer. Elevated WC and triglycerides were (inversely) associated with prostate cancer. MetS models were only poor to moderate discriminators for all cancer outcomes.

Conclusions

We show that the MetS is (inversely) associated with prostate cancer, but is not associated with overall, colorectal or breast cancer. Although, persons with five positive components of the MetS are at a 1.2 and 2.1 increased risk for overall and colorectal cancer, respectively, and these associations appear to be driven, largely, by elevated WC and BP. We also demonstrate that the MetS is only a moderate discriminator of cancer risk.

El texto completo de este artículo está disponible en PDF.

Keywords : Cancer, Epidemiology, Metabolic syndrome, Prediction

Esquema

Definition of covariates

Definition of the metabolic syndrome

Statistical analysis

Results

Discussion

Comparisons with literature

Strengths and weaknesses

Conclusions

Disclosure of interest

Authors' contributions

Exportación

Vol 41 - N° 6

P. 463-469 - décembre 2015 Regresar al número

Artículo precedente

Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring
L. Monnier, A. El Azrak, N. Lessan, D. Rochd, C. Colette, F. Bonnet

| Artículo siguiente

Hypoglycaemic episodes in patients with type 2 diabetes – risk factors and associations with patient-reported outcomes: The PANORAMA Study
D. Simon, P. de Pablos-Velasco, K.G. Parhofer, L. Gönder-Frederick, I. Duprat Lomon, H. Vandenberghe, E. Eschwège, C. Bradley

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

conectar o crear una cuenta

The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components? - 05/12/15

Abstract

Aims

Materials and methods

Results

Conclusions

Esquema

Exportación citas

Fichero

Contenido

Mi cuenta

Aide & support

Declaración CNIL